CClinicalTrials.gg
CompletedNCT03709615Updated May 11, 2021

Therapeutic Processes in iCBT for SAD

An interventional study of Internet delivered CBT for social anxiety disorder in Social Anxiety Disorder and Social Phobia, sponsored by University of Haifa. Completed at 1 site in Israel. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-05-11.

Sponsored by University of Haifa · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The current study examines therapeutic processes during internet-based cognitive-behavioral therapy for social anxiety disorder. Participants will be randomized to either treatment or wait-list conditions. Participants in the wait-list condition will receive active treatment following the wait-list period.

Read the detailed description

Internet-based cognitive-behavioral therapy (iCBT) is an effective treatment for social anxiety disorder (SAD). However, little is known about the processes and mechanisms of change in this treatment. Compared to face to face (FTF) treatments, online interventions may operate through partially different mechanisms of change due to the text-based nature of the interaction and the reduced level of therapist involvement. The present randomized controlled trial will examine therapeutic processes during iCBT for SAD including the presence of sudden gains and their relationship to outcome, the relationship between anxiety and depressive symptoms along the course of treatment, changes in the therapeutic alliance and attrition from therapy. Moreover, we will compare iCBT for SAD with a wait-list control group and utilize weekly measurements of anxiety, depression, and SAD-related cognitions in both groups. This will facilitate comparison between temporal processes in both conditions and also shed light on processes occurring in wait-list conditions.

02

Conditions studied

  • Social Anxiety Disorder
  • Social Phobia

Keywords

  • Social anxiety disorder
  • iCBT
  • Therapeutic processes
03

In context

Anxiety Disorders

4,868 studies on the registry are indexed under Anxiety Disorders; 1,388 are open to participants now.

This study's enrollment of 120 is above the median of 80 across 4,170 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

University of Haifa is the lead sponsor of 101 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Meeting DSM-5 criteria for social anxiety disorder.
  • Fluency in Hebrew
  • Access to internet

Exclusion criteria

Exclusion Criteria:

  • Substance use disorders
  • Past or present psychosis
  • High levels of suicidality
  • Changes in pharmacological treatment 3 months or less prior to the start of the trial
  • Participation in other psychotherapeutic treatments during the trial
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • No intervention
    Wait list

    Wait list condition with no active treatment, length of 10 weeks, with weekly measurements.

  • Experimental
    Intervention- active treatment

    Internet delivered CBT for social anxiety disorder

    Behavioral: Internet delivered CBT for social anxiety disorder

Interventions

  • BehavioralInternet delivered CBT for social anxiety disorder

    An internet-based CBT for social anxiety based on a protocol from Andersson et al., 2006: "Internet-based self-help with therapist feedback and in vivo group exposure for social phobia: a randomized controlled trial."

06

What researchers measure

Primary outcomes

  1. Social anxiety severity

    Post treatment Liebowitz Social Anxiety Scale (LSAS). Score ranges from 0 to 144 where higher score indicates more sever social anxiety

    Time frame: Change from Baseline LSAS at post treatment (12 weeks)

  2. Diagnosis of SAD based on clinical interview

    Diagnoses derived from the Anxiety and Related Disorders Interview Schedule for DSM-5 (ADIS)

    Time frame: Change from Baseline ADIS diagnosis at post treatment (12 weeks)

  3. Social anxiety severity

    Follow-up Liebowitz Social Anxiety Scale (LSAS). Score ranges from 0 to 144 where higher score indicates more sever social anxiety

    Time frame: Change from Baseline LSAS at 6 months follow-up

Secondary outcomes

  1. Social anxiety severity - additional measure

    Post treatment Social Phobia Inventory (SPIN). Score ranges from 0 to 68 where higher score indicates more sever social anxiety

    Time frame: Change from Baseline SPIN at post treatment (12 weeks)

  2. Social anxiety severity - additional measure

    Post treatment Social Phobia Inventory (SPIN). Score ranges from 0 to 68 where higher score indicates more sever social anxiety

    Time frame: Change from Baseline SPIN at 6 months follow-up

Other outcomes

  1. Depressive symptoms severity

    Post treatment Beck Depression Inventory II, (BDI-II). Score ranges from 0 to 63 where higher score indicates more sever depression.

    Time frame: Change from Baseline BDI-II at post treatment (12 weeks)

  2. Depressive symptoms severity

    Post treatment Beck Depression Inventory II, (BDI-II). Score ranges from 0 to 63 where higher score indicates more sever depression.

    Time frame: Change from Baseline BDI-II at 6 months follow-up

07

Study locations

1 site
  • University of Haifa
    Haifa, Israel
08

References and documents

Publications

  • Shalom JG, Strauss AY, Huppert JD, Andersson G, Agassi OD, Aderka IM. Predicting sudden gains before treatment begins: An examination of pretreatment intraindividual variability in symptoms. J Consult Clin Psychol. 2020 Sep;88(9):809-817. doi: 10.1037/ccp0000587. Epub 2020 Jun 25. PubMed 32584117 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03709615
Lead sponsor
University of Haifa
Collaborators
Hebrew University of Jerusalem, Linkoeping University
Responsible party
Idan Moshe Aderka (Principal Investigator, University of Haifa) — Principal investigator
First posted
Oct 17, 2018
Start date
Dec 20, 2017
Primary completion
Jun 20, 2020
Completion
Jun 20, 2020
Last update
May 11, 2021

Study contacts

Idan M Aderka, PhD
principal investigator · University of Haifa

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion